The therapeutic potential of ribozymes

Blood

Volumn 91, Issue 2, 1998, Pages 371-382

  James, Helen A ^a   Gibson, Lan ^a  

^a UNIVERSITY OF EAST ANGLIA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; RIBOZYME; TRANSFER RNA;

CHROMOSOME TRANSLOCATION; ENZYME ACTIVITY; ENZYME CHEMISTRY; GENE EXPRESSION REGULATION; GENE MUTATION; GENE REPRESSION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; REVIEW; RNA CLEAVAGE; RNA SPLICING; VIRUS INHIBITION;

EID: 0031973036     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v91.2.371.371_371_382     Document Type: Review

References (155)

1. Rossi JJ, Cantin EM, Sarver N, Chang PF: The potential use of catalytic RNAs in therapy of HIV infection and other diseases. Pharmacol Ther 50:245, 1991
2. Sullenger BA, Cech TR: Ribozyme-mediated repair of defective. mRNA by targeted trans-splicing. Nature 371:619, 1994
3. James HA, Turner PC: Ribozymes Essays Biochem 29 175, 1995
4. Cedergren R: RNA-The catalyst. Biochem Cell Biol 68:903, 1990
5. Maniatis T, Reed R: The role of small nuclear ribonucleoprotein particles in pre-mRNA splicing. Nature 325:673, 1987
6. Cech TR, Zaug AJ, Grabowski PJ: In vitro splicing of the ribosomal RNA precursor of Tetrahymena: Involvment of a guanosine nucleotide in the excision of the intervening sequence. Cell 27:487, 1981
7. Kruger K, Grabowski PJ, Zaug AJ, Sands J, Gottschling DE, Cech TR: Self-splicing RNA: Autoexcision and autocyclization of the ribosomal RNA intervening sequence of Tetrahymena. Cell 31:147, 1982
8. Been MD, Cech TR: One binding site determines sequence specificity of Tetrahymena pre-rRNA self-splicing, trans-splicing and RNA enzyme activity. Cell 47:207, 1986
9. Garriga G, Lambowitz AM, Inoue T, Cech TR: Mechanism of recognition of the 5′ splice site in self-splicing group I introns. Nature 322:86, 1986
10. Inoue T, Sullivan FX, Cech TR: New reactions of the ribosomal RNA precursor of Tetrahymena and the mechanism of self-splicing. J Mol Biol 189:143, 1986
11. Suh ER, Waring RB: Base pairing between the 3′ exon and an internal guide sequence increases 3′ splice site specificity in the Tetrahymena self-splicing rRNA intron. Mol Cell Biol 10:2960, 1990
12. Cate JH, Gooding AR, Podell E, Zhou K, Golden BL, Kundrot CE, Cech TR, Doudna JA: Crystal structure of a group I ribozyme domain: principles of RNA packing. Science 273:1678, 1996
13. Tanner MA, Cech TR: Joining the two domains of a group I ribozyme to form the catalytic core. Science 275:847, 1997
14. Golden BL, Cech TR: Conformational switches involved in orchestrating the successive steps of group I RNA splicing. Biochemistry 35:3754, 1996
15. Mei R, Herschlag D: Mechanistic investigations of a ribozyme derived from the Tetrahymena group I intron - Insights into catalysis and the second step of self-splicing. Biochemistry 35:5796, 1996
16. Sjogren AS, Pettersson E, Sjoberg BM, Stromberg R: Metal ion interaction with cosubstrate in self-splicing of group I introns. Nucleic Acids Res 25:648, 1997
17. Jones JT, Lee S-W, Sullenger BA: Tagging ribozyme reaction sites to follow irons-splicing in mammalian cells. Nat Med 2:643, 1996
18. Peebles CL, Perlman PS, Mecklenburg KL, Petrillo ML, Yabor JH, Jarrell KA, Cheng H-L: A self-splicing RNA excises an intron lariat. Cell 44:213, 1986
19. Daniels DL, Michels WJ Jr, Pyle AM: Two competing pathways for self-splicing by group II introns: A quantitative analysis of in vitro reaction rates and products. J Mol Biol 256:31, 1996
20. Jacquier A, Rosbash M: Efficient trans-splicing of a yeast mitochondrial RNA group II intron implicates a strong 5′ exon-intron interaction. Science 234:1099, 1986
21. Morl M, Schmelzer C: Integration of group II intron b11 into a foreign RNA by reversal of the self-splicing reaction in vitro. Cell 60:629, 1990
22. Mikheeva S, JarreII KA: Use of engineered ribozymes to catalyze chimeric gene assembly. Proc Natl Acad Sci USA 93:7486, 1996
23. Darr SC, Brown JW, Pace NR: The varieties of ribonuclease P. Trends Bioi Sci 17:178, 1992
24. Guerrier-Takada C, Gardiner K, Marsh T, Pace N, Altaian S: The RNA moiety of ribonuclease P is the Catalytic subunit of the enzyme. Cell 35:849, 1983
25. Guerrier-Takada C, Haydock K, Allen L, Altman S: Metal ion requirements and other aspects of the reaction catalyzed by M1 RNA, the RNA subunit of ribonucleases P from Escherichia coli. Biochemistry 25:1509, 1986
26. Yuan Y, Altman S: Selection of guide sequences that direct efficient cleavage of mRNA by human ribonuclease P. Science 263: 1269, 1994
27. George ST, Werner M, Nordstrom JL, Goldberg AR: Derivation of a small external guide sequence capable of inducing cleavage of target RNA by human RNase P. J Cell Biochem S19A:209, 1995 (abstr)
28. Werner M, Iannuccilli WJ, George ST, Ma MYX, Goldberg AR: Characterization of the external guide sequence directed cleavage reaction of target RNA molecules with ribonuclease P. J Cell Biochem S19A:213, 1995 (abstr)
29. Li Y, Altman S: Cleavage by RNase P of gene N mRNA reduces bacteriophage 1 burst size. Nucleic Acids Res 24:835, 1996
30. Hutchins CJ, Rathjen PD, Forster AC, Symons RH: Selfcleavage of plus and minus RNA transcripts of avocado sunblotch viroid. Nucleic Acids Res 14:3627, 1986
31. Hernandez C, Flores R: Plus and minus RNAs of peach latent mosaic viroid self-cleave in vitro via hammerhead structures. Proc Natl Acad Sci USA 89:3711, 1992
32. Beaudry D, Bussiere F, Lareau F, Lessard C, Perreault J-P: The RNA of both polarities of the peach latent mosaic viroid self-cleaves in vitro by single hammerhead structures. Nucleic Acids Res 23:745, 1995
33. Robertson HD, Rosen DL, Branch AD: Cell-free synthesis and processing of an infectious dimeric transcript of potato spindle tuber viroid RNA. Virology 142:441, 1985
34. Miller WA, Hercus T, Waterhouse PM, Gerlach WL: A satellite RNA of barley yellow dwarf virus contains a novel hammerhead structure in the self-cleavage domain. Virology 183:711, 1991
35. Buzayan JM, Gerlach WL, Bruening G: Non-enzymatic cleavage and ligation of RNAs complementary to a plant virus satellite RNA. Nature 323:349, 1986
36. Prody GA, Bakos JT, Buzayan JM, Schneider IR, Bruening G: Autolytic processing of dimeric plant virus satellite RNA. Science 231:1577, 1986
37. Forster AC, Symons RH: Self-cleavage of plus and minus RNAs of a virusoid and a structural model for the active sites. Cell 49:211, 1987
38. Davies C, Haseloff J, Symons RH: Structure, self-cleavage and replication of two viroid-like satellite RNAs (virusoids) of subterranean clover mottle virus. Virology 177:216, 1990
39. Epstein LM, Gall JG: Self-cleaving transcripts of satellite DNA from the newt. Cell 48:535, 1987
40. Hampel A, Tritz R: RNA catalytic properties of the minimum (-) sTRSV sequence. Biochemistry 28:4929, 1989
41. Chowrira BM, Burke JM: Binding and cleavage of nucleic acids by the 'hairpin' ribozyme. Biochemistry 30:8518, 1991
42. Berzal-Herranz A, Joseph S, Chowrira BM, Butcher SE, Burke JM: Essential nucleotide sequences and secondary structure elements of the hairpin ribozyme. EMBO J 12:2567, 1993
43. DeYoung MB, Siwkowski AM, Lian Y, Hampel A: Catalytic properties of hairpin ribozymes derived from chicory yellow mottle virus and arabis mosaic virus satellite RNAs. Biochemistry 34:15785, 1995
44. Wu H-N, Lin Y-J, Lin F-P, Makino S, Chang M-F, Lai MMC: Human hepatitis δ virus RNA subfragments contain an autocleavage activity. Proc Natl Acad Sci USA 86:1831, 1989
45. Perrotta AT, Been MD: A pseudoknot-like structure required for efficient self-cleavage of hepatitis delta virus RNA. Nature 350:434, 1991
46. Wu H-N, Wang Y-J, Hung C-F, Lee H-J, Lai MMC: Sequence and structure of the catalytic RNA of hepatitis delta virus genomic RNA. J Mol Biol 223:233, 1992
47. Saville BJ, Collins RA: A site-specific self-cleavage reaction performed by a novel RNA in Neurospora mitochondria. Cell 61:685, 1990
48. Collins RA, Olive JE: Reaction conditions and kinetics of self-cleavage of a ribozyme derived from Neurospora VS RNA. Biochemistry 32:2795, 1993
49. Beattie TL, Olive JE, Collins RA: A secondary-structure model for the self-cleaving region of Neurospora VS RNA. Proc Natl Acad Sci USA 92:4686, 1995
50. Rastogi T, Beattie TL, Olive JE, Collins RA: A long-range pseudoknot is required for activity of the Neurospora VS ribozyme. EMBO J 15:2820, 1996
51. Haseloff J, Gerlach WL: Simple RNA enzymes with new and highly specific endoribonuclease activities. Nature 334:585, 1988
52. Hertel KJ, Pardi A, Uhlenbeck OC, Koizumi M, Ohtsuka E, Uesugi S, Cedergren R, Eckstein F, Gerlach WL, Hodgson R, Symons RH: Numbering system for the hammerhead. Nucleic Acids Res 20:3252, 1992
53. Branch AD, Robertson HD: A replication cycle for viroids and other small infectious RNA's. Science 223:450, 1984
54. Sigurdsson ST, Eckstein F: Structure-function relationships of hammerhead ribozymes: From understanding to applications. Trends Biotech 13:286, 1995
55. Dahm SC, Uhlenbeck OC: Role of divalent metal ions in the hammerhead RNA cleavage reaction. Biochemistry 30:9464, 1991
56. Yarus M: How many catalytic RNAs? Ions and the Cheshire cat conjecture. FASEB J 7:31, 1993
57. Pley HW, Flaherty KM, McKay DB: Three-dimensional structure of a hammerhead ribozyme. Nature 372:68, 1994
58. Scott WG, Finch JT, Klug A: The crystal structure of an all-RNA hammerhead ribozyme: A proposed mechanism for RNA catalytic cleavage. Cell 81:991, 1995
59. Tuschl T, Gohlke C, Jovin TM, Westhof E, Eckstein F: A three-dimensional model for the hammerhead ribozyme based on fluorescence measurements. Science 266:785, 1994
60. Scott WG, Murray JB, Arnold JRP, Stoddard BL, Klug A: Capturing the structure of a catalytic RNA intermediate: The hammerhead ribozyme. Science 274:2065, 1996
61. Guo HCT, Collins RA: Efficient trans-cleavage of a stem-loop RNA substrate by a ribozyme derived from Neurospora VS RNA. EMBO J 14:368, 1995
62. Branch AD, Robertson HD: Efficient trans cleavage and a common structural motif for the ribozymes of the human hepatitis δ agent. Proc Natl Acad Sci USA 88:10163, 1991
63. Gottlieb PA, Prasad Y, Smith JB, Williams AP, Dinter-Gottlieb G: Evidence that alternate foldings of the hepatitis δ RNA confer varying rates of self-cleavage. Biochemistry 33:2802, 1994
64. Branch AD, Polaskova JA: 3-D models of the antigenomic ribozyme of the hepatitis delta agent with eight new contacts suggested by sequence-analysis of 188 cDNA clones. Nucleic Acids Res 23:4180, 1995
65. Jeng K-S, Daniel A, Lai MMC: A pseudoknot ribozyme structure is active in vivo and required for hepatitis delta virus RNA replication. J Virol 70:2403, 1996
66. Been MD: Cis-and trans-acting ribozymes from a human pathogen, hepatitis delta virus. Trends Biol Sci 19:251, 1994
67. Kawakami J, Yuda K, Suh Y-A, Kumar PKR, Nishikawa F, Maeda H, Taira K, Ohtsuka E, Nishikawa S: Constructing an efficient trans-acting genomic HDV ribozyme. FEBS Lett 394:132, 1996
68. Wagner RW: Gene inhibition using antisense oligodeoxynucleotides. Nature 372:333, 1994
69. Lodish H, Baltimore D, Berk A, Zipursky SL, Matsudaira P, Darnell J: Molecular Cell Biology. New York, NY, Scientific American, 1995, p 641
70. Kobayashi H, Dorai T, Holland JF, OhnumaT: Reversal of drug sensitivity in multidrug-resistant tumor cells by an MDR1 (PGY1) ribozyme. Cancer Res 54:1271, 1994
71. Kiehntopf M, Brach MA, Licht T, Petschauer S, Karawajew L, Kirschning C, Herrmann F: Ribozyme-mediated cleavage of the MDR-1 transcript restores chemosensitivity in previously resistant cancer cells. EMBO J 13:4645, 1994
72. Kashani-Sabet M, Funato T, Florenes VA, Fodstad O, Scanlon KJ: Suppression of the neoplastic phenotype in vivo by an anti-ras ribozyme. Cancer Res 54:900, 1994
73. Ohta Y, Kijima H, Ohkawa T, Kashani-Sabet M, Scanlon KJ: Tissue-specific expression of an anti-ras ribozyme inhibits proliferation of human malignant melanoma cells. Nucleic Acids Res 24:938, 1996
74. Lange W, Cantin EM, Finke J, Dolken G: In vitro and in vivo effects of synthetic ribozymes targeted against BCR/ABL mRNA. Leukemia 7:1786, 1993
75. Snyder DS, Wu Y, Wang JL, Rossi JJ, Swiderski P, Kaplan BE, Forman SJ: Ribozyme-mediated inhibition of bcr-abl gene expression in a Philadelphia chromosome-positive cell line. Blood 82:600, 1993
76. Leopold LH, Shore SK, Newkirk TA, Reddy RMV, Reddy EP: Multi-unit ribozyme-mediated cleavage of bcr-abl mRNA in myeloid leukemias. Blood 85:2162, 1995
77. Mills KI, Walsh V, Gilkes AF, Goringe A, Twomey C, James HA, Gibson I: In vitro ribozyme treatment of 32D cells expressing a BCR-ABL construct prolongs the survival of SCID mice. Blood 88:577a, 1996 (abstr, suppl 1)
78. Czubayko F, Schulte AM, Berchem GJ, Wellstein A: Melanoma angiogenesis and metastasis modulated by ribozyme targeting of the secreted growth factor pleiotrophin. Proc Natl Acad Sci USA 93:14753, 1996
79. Zhou C, Bahner IC, Larson GP, Zaia JA, Rossi JJ, Kohn DB: Inhibition of HIV-1 in human T-lymphocytes by retrovirally transduced anti-tat and rev hammerhead ribozymes. Gene 149:33, 1994
80. Leavitt MC, Yu M, Wong-Staal F, Looney DJ: Ex vivo transduction and expansion of CD4+ lymphocytes from HIV+ donors: Prelude to a ribozyme gene therapy trial. Gene Ther 3:599, 1996
81. Bauer G, Valdez P, Kearns K, Bahner I, Wen SF, Zaia JA, Kohn DB: Inhibition of human immunodeficiency virus-1 (HIV-1) replication after transduction of granulocyte colony-stimulating factor-mobilized CD34(+) cells from HIV-1-infected donors using retroviral vectors containing anti-HIV-1 genes. Blood 89:2259, 1997
82. Beck J, Nassal M: Efficient hammerhead ribozyme-mediated cleavage of the structured hepatitis B virus encapsidation signal in vitro and in cell extracts, but not in intact cells. Nucleic Acids Res 23:4954, 1995
83. Welch PJ, Tritz R, Yei S, Leavitt M, Yu M, Barber J: A potential therapeutic application of hairpin ribozymes: In vitro and in vivo studies of gene therapy for hepatitis C virus infection. Gene Ther 3:994, 1996
84. Flory CM, Pavco PA, Jarvis TC, Lesch ME, Wincott FE, Beigelman L, Hunt SW III, Schrier DJ: Nuclease-resistant ribozymes decrease stromelysin mRNA levels in rabbit synovium following exogenous delivery to the knee joint. Proc Natl Acad Sci USA 93:754, 1996
85. Cameron FH, Jennings PA: Multiple domains in a ribozyme construct confer increased suppressive activity in monkey cells. Antisense Res Dev 4:87, 1994
86. Steinecke P, Herget T, Schreier PH: Expression of a chimeric ribozyme gene results in endonucleolytic cleavage of target mRNA and a concomitant reduction of gene expression in vivo. EMBO J 11:1525, 1992
87. Davies C, Haseloff J, Symons RH: Structure, self-cleavage and replication of two viroid-like satellite RNAs (virusoids) of subterranean clover mottle virus. Virology 177:216, 1990
88. Heidenreich O, Xu X, Nerenberg M: A hammerhead ribozyme Cleaves its target RNA during RNA preparation. Antisense Nucleic Acid Drug Dev 6:141, 1996
89. Ohta Y, Kijima H, Kashani-Sabet M, Scanlon KJ: Suppression of the malignant phenotype of melanoma cells by anti-oncogene ribozymes. J Invest Dermatol 106:275, 1996
90. James H, Mills K, Gibson I: Investigating and improving the specificity of ribpzymes directed against the bcr-abl translocation. Leukemia 10:1054, 1996
91. Lange W, Daskalakis M, Finke J, Dolken G: Comparison of different ribozymes for efficient and specific cleavage of BCR/ABL related mRNAs. FEBS Lett 338:175, 1994
92. Wright L, Wilson SB, Milliken S, Biggs J, Kearney P: Ribozymemediated cleavage of the bcr/abl transcript expressed in chronic myeloid leukemia. Exp Hematol 21:1714, 1993
93. Shore SK, Nabissa PM, Reddy EP: Ribozyme-mediated cleavage of the BCRABL oncogene transcript: In vitro cleavage of RNA and in vivo loss of p210 protein-kinase activity. Oncogene 8:3183, 1993
94. Kozu T, Sueoka E, Okabe S, Sueoka N, Komori A, Fujiki H: Designing of chimeric DNA/RNA hammerhead ribozymes to be targeted against AML1/MTG8 mRNA. J Cancer Res Clin Oncol 122:254, 1996
95. + lymphocyte-derived cell lines conferred by using retroviral vectors expressing an HIV-1 RNA-specific ribozyme. J Virol 65:5531, 1991
96. Lo KMS, Biasolo MA, Dehni G, Palu G, Haseltine WA: Inhibition of replication of HIV-1 by retroviral vectors expressing tat-antisense and anti-tat ribozyme RNA. Virology 190:176, 1992
97. Yamada O, Yu M, Yee J-K, Kraus G, Looney D, Wong-Staal F: Intracellular immunization of human T cells with a hairpin ribozyme against human immunodeficiency virus type I. Gene Ther 1:38, 1994
98. Zhou C, Bahner I, Rossi JJ, Kohn DB: Expression of hammerhead ribozymes by retroviral vectors to inhibit HIV-1 replication: Comparison of RNA levels and viral inhibition. Antisense Nucleic Acid Drug Dev 6:17, 1996
99. Wong-Staal F, Poeschla E, Looney D, Yu M, Leavitt M, Yamada O, Yee J-K: RAC Submission # 9309-057. 1993
100. Lieber A, He CY, Polyak SJ, Gretch DR, Barr D, Kay MA: Elimination of hepatitis C virus RNA in infected human hepatocytes by adenovirus-mediated expression of ribozymes. J Virol 70:8782, 1996
101. Sakamoto N, Wu CH, Wu GY: Intracellular cleavage of hepatitis C virus RNA and inhibition of viral protein translation by hammerhead ribozymes. J Clin Invest 98:2720, 1996
102. Tang XB, Hobom G, Luo D: Ribozyme mediated destruction of influenza A virus in vitro and in vivo. J Med Virol 42:385, 1994
103. Larsson S, Hotchkiss G, Andang M, Nyholm T, Inzunza J, Jansson I, Ahrlund-Richter L: Reduced β2 microglobulin mRNA levels in transgenic mice expressing a designed hammerhead ribozyme. Nucleic Acids Res 22:2242, 1994
104. Lieber A, Kay MA: Adenovirus-mediated expression of ribozymes in mice. J Virol 70:3153, 1996
105. Desjardins JP, Sproat BS, Beijer B, Blaschke M, Dunkel M, Gerdes W, Ludwig J, Reither V, Rupp T, Iversen PL: Pharmacokinetics of a synthetic, chemically modified hammerhead ribozyme against the rat cytochrome P-450 3A2 mRNA after single intravenous injections. J Pharmacol Exp Ther 278:1419, 1996
106. Lyngstadaas SP, Risnes S, Sproat BS, Thrane PS, Prydz HP: A synthetic, chemically modified ribozyme eliminates amelogenin, the major translation product in developing mouse enamel in vivo. EMBO J 14:5224, 1995
107. Sokol DL, Murray JD: Antisense and ribozyme constructs in transgenic animals. Transgenic Res 5:363, 1996
108. Zhao JJ, Pick L: Generating loss-of-function phenotypes of the fushi tarazu gene with a targeted ribozyme in Drosophila. Nature 365:448, 1993
109. Scanlon KJ, Jiao L, Funato T, Wang W, Tone T, Rossi JJ, Kashani-Sabet M: Ribozyme-mediated cleavage of c-fos mRNA reduces gene expression of DNA synthesis enzymes and metallothionein. Proc Natl Acad Sci USA 88:10591, 1991
110. Turck J, Pollock AS, Lee LK, Marti H-P, Lovett DH: Matrix metalloproteinase 2 (gelatinase A) regulates glomerular mesangial cell proliferation and differentiation. J Biol Chem 271:15074, 1996
111. Mazzolini L, Axelos M, Lescure N, Yot P: Assaying synthetic ribozymes in plants: high-level expression of a functional hammerhead structure fails to inhibit target gene activity in transiently transformed protoplasts. Plant Mol Biol 20:715, 1992
112. Perriman R, Graf L, Gerlach WL: A ribozyme that enhances gene suppression in tobacco protoplasts, Antisense Res Dev 3:253, 1993
113. Atkins D, Gerlach WL: Artificial ribozyme and antisense gene expression in Saccharomyces cerevisiae. Antisease Res Dev 4:109, 1994
114. Atkins D, Patrikakis M, Izant JG: The ade6 gene of the fission yeast as a target for antisense and ribozyme RNA-mediated suppression. Antisense Res Dev 5:295, 1995
115. Mclntyre CL, Bettenay HM, Manners JM: Strategies for the suppression of peroxidase gene expression in tobacco. II. In vivo suppression of peroxidase activity in transgenic tobacco using ribozyme and antisense constructs. Transgenic Res 5:263, 1996
116. Turner PC (Ed): Methods in Molecular Biology 74: Ribozyme Protocols. Totowa, NJ, Humana, 1997
117. Gibson I (Ed): Antisense and Ribozyme Methodology. Laboratory Companion. Weinheim, Germany, Chapman & Hall GmbH, 1997
118. Zoumadakis M, Neubert WJ, Tabler M: The influence of imperfectly paired helices I and III on the catalytic activity of hammerhead ribozymes. Nucleic Acids Res 22:5271, 1994
119. Xing Z, Whitton JL: Ribozymes which cleave Arenavirus RNAs: Identification of susceptible target sites and inhibition by target site secondary structure. J Virol 66:1361, 1992
120. Kronenwett R, Haas R, Sczakiel G: Kinetic selectivity of complementary nucleic acids: bcr-abl-directed antisense RNA and ribozymes. J Mol Biol 259:632, 1996
121. Auron PE, Rindone WP, Vary CPH, Celentano JJ, Vournakis JN: Computer-aided prediction of RNA secondary structures. Nucleic Acids Res 10:403, 1982
122. Jacobson AB, Good L, Simonetti J, Zuker M: Some simple computational methods to improve the folding of large RNAs. Nucleic Acids Res 12:45, 1984
123. Herschlag D: Implications of ribozyme kinetics for targeting the cleavage of specific RNA molecules in vivo: More isn't always better. Proc Natl Acad Sci USA 88:6921, 1991
124. Sioud M: Effects of variations in length of hammerhead ribozyme antisense arms upon the cleavage of longer RNA substrates. Nucleic Acids Res 25:333, 1997
125. Tabler M, Homann M, Tzortzakaki S, Sczakiel G: A threenucleotide helix I is sufficient for full activity of a hammerhead ribozyme: Advantages of an asymmetric design. Nucleic Acids Res 22:3958, 1994
126. Crisell P, Thompson S, James W: Inhibition of HIV-1 replication by ribozymes that show poor activity in vitro. Nucleic Acids Res 21:5251, 1993
127. Hormes R, Homann M, Oelze I, Marschall P, Tabler M, Eckstein F, Sczakiel G: The subcellular localization and length of hammerhead ribozymes determine efficacy in human cells. Nucleic Acids Res 25:769, 1997
128. Chapman KB, Szostak JW: In vitro selection of catalytic RNAs. Curr Opin Sruct Biol 4:618, 1994
129. Joyce GF: In vitro evolution of nucleic acids. Curr Opin Sruct Biol 4:331, 1994
130. bcr-abl tyrosine kinase autophosphorylation by oligodeoxynucleotides of defined sequence and backbone structure. Nucleic Acids Res 22:2150, 1994
131. Bergan RC, Kyle E, Connell Y, Neckers L: Inhibition of protein-tyrosine kinase activity in intact cells by the aptameric action of oligodeoxynucleotides. Antisense Res Dev 5:33, 1995
132. Stull RA, Szoka FC Jr: Antigene, ribozyme and aptamer nucleic acid drugs: Progress and prospects. Pharm Res 12:465, 1995
133. Chen C-J, Banerjea AC, Harmison GG, Haglund K, Schubert M: Multitarget-ribozyme directed to cleave at up to nine highly conserved HIV-1 env RNA regions inhibits HIV-1 replication -Potential effectiveness against most presently sequenced HIV-1 isolates. Nucleic Acids Res 20:4581, 1992
134. Leopold LH, Shore SK, Reddy EP: Multi-unit anti-BCR-ABL ribozyme therapy in chronic myelogenous leukemia. Leuk Lymphoma 22:365, 1996
135. Pieken WA, Olsen DB, Benseler F, Aurup H, Eckstein F: Kinetic characterization of ribonuclease-resistant 2′ modified hammerhead ribozymes. Science 253:314, 1991
136. Paolella G, Sproat BS, Lamond AI: Nuclease resistant ribozymes with high catalytic activity. EMBO J 11:1913, 1992
137. Bertrand E, Castanotto D, Zhou C, Carbonnelle C, Lee NS, Good P, Chatterjee S, Grange T, Pictet R, Kahn D, Engelke D, Rossi JJ: The expression cassette determines the functional aciyity of ribozymes in mammalian cells by controlling their intracellular localization. RNA 3:75, 1997
138. Sullenger BA: Ribozyme-mediated repair of RNAs encoding mutant tumor suppressors. Cytokines Mol Ther 2:201, 1996
139. Sarver N, Cantin EM, Chang PS, Zaia JA, Ladne PA, Stephens DA and Rossi JJ: Ribozymes as potential anti-HIV-1 therapeutic agents. Science 247:1222, 1990
140. Good PD, Krikos AJ, Li SXL, Bertrand E, Lee NS, Giver L, Ellington A, Zaia JA, Rossi JJ, Engelke DR: Expression of small, therapeutic RNAs in human cell nuclei. Gene Ther 4:45, 1997
141. Thompson JD, Ayers DF, Malmstrom TA, McKenzie TL, Ganousis L, Chowrira BM, Couture L, Stinchcomb DT: Improved accumulation and activity of ribozymes expressed from a tRNA-based RNA polymerase III promoter. Nucleic Acids Res 23:2259, 1995
142. Sullenger BA, Cech TR: Tethering ribozymes to a retroviral packaging signal for destruction of viral RNA. Science 262:1566, 1993
143. Lawrence JB, Singer RH: Intracellular localization of messenger RNAs for cytoskeletal proteins. Cell 45:407, 1986
144. Ding D, Lipshitz HD: Localized RNAs and their functions. Bioessays 15:651, 1993
145. Twomey CM, Gibson I: The intracellular distribution of fluorescently labeled ribozyme in the 32Db3a2 murine cell line, in Molecular and Cellular Biology of Gene Therapy. Keystone Symposia. Snowbird, UT, 1997, p 71 (abstr)
146. Savelyeva NN, Gibson I: Unprotected ribozymes against c-myc mRNA cleave the RNA in nuclei isolated from HL-60 cells, in Molecular and Cellular Biology of Gene Therapy. Keystone Symposia. Snowbird, UT, 1997, p 68 (abstr)
147. Bertrand E, Fromont-Racine M, Pictet R, Grange T: Visualisation of the interaction of a regulatory protein with RNA in vivo. Proc Natl Acad Sci USA 90:3496, 1993
148. Stein CA, Krieg A: Problems in the interpretation of data derived from the in vitro and in vivo use of antisense oligodeoxynudeotides. Antisense Res Dev 4:67, 1994 (editorial)
149. Yaswen P, Stampfer MR, Ghosh K, Cohen JS: Effects of sequence of thioated oligonucleotides on cultured human mammary epithelial cells. Antisense Res Dev 3:67, 1993
150. Vaerman JL, Lammineur C, Moureau P, Lewalle P, Deldime F, Blumenfeld M, Martial P: BCR-ABL antisense oligodeoxyribonucleotides suppress the growth of leukemic and normal hematopoienc cells by a sequence-specific but nonantisense mechanism. Blood 86:3891, 1995
151. von Ahsen U, Davies J, Schroeder R: Antibiotic inhibition of group I ribozyme function. Nature 353:368, 1991
152. Stage TK, Hertel KJ, Uhlenbeck OC: Inhibition of the hammerhead ribozyme by neomycin. RNA 1:95, 1995
153. Murray JB, Arnold JRP; Antibiotic interactions with the hammerhead ribozyme - Tetracyclines as a new class of hammerhead inhibitor. Biochem J 317:855, 1996
154. Rogers J, Chang AH, von Ahsen U, Schroeder R, Davies J: Inhibition of the self-cleavage reaction of the human hepatitis delta virus ribozyme by antibiotics. J Mol Biol 259:916, 1996
155. Olive JE, De Abreu DM, Rastogi T, Andersen AA, Mittermaier AK, Beattie TL, Collins RA: Enhancement of Neurospora VS ribozyme cleavage by tuberaetinomycin antibiotics. EMBO J 14:3247, 1995